(Q57315629)
Statements
New medications targeting triglyceride-rich lipoproteins: Can inhibition of ANGPTL3 or apoC-III reduce the residual cardiovascular risk? (English)
0 references
May 2018
0 references
272
0 references
27-32
0 references